AZD0901 bei Teilnehmern mit fortgeschrittenen soliden Tumoren, die Claudin18.2 exprimieren
Eine offene, multizentrische Phase-II-Studie zur Bewertung der Sicherheit, Verträglichkeit, Wirksamkeit, Pharmakokinetik und Immunogenität von AZD0901 als Monotherapie und in Kombination mit Krebsmedikamenten bei Teilnehmern mit fortgeschrittenen soliden Tumoren, die Claudin 18.2 exprimieren.
The purpose of this study is to assess the safety, tolerability, efficacy, pharmacokinetics (PK), and immunogenicity of AZD0901 as monotherapy and in combination with anti-cancer agents in participants with locally advanced unresectable or metastatic solid tumours expressing CLDN18.2 .
Studienübersicht
Status
Bedingungen
Detaillierte Beschreibung
This open-label, multi-centre study consists of individual sub studies, each evaluating the safety and tolerability of AZD0901.
Sub study 1 will investigate the safety, tolerability, and anti-tumour activity of AZD0901 monotherapy in participants with advanced or metastatic gastric esophageal cancer expressing CLDN18.2. Participants will receive AZD0901 monotherapy via intravenous (IV) infusion and will be randomised in to one of 2 arms.
Sub study 2 will consist of two parts, a safety run-in and a dose expansion part to investigate the safety and efficacy of AZD0901 in combination with different chemotherapy agents in participants with pancreatic cancer. Substudy 3 will investigate the safety, tolerability, and anti-tumour activity of AZD0901 monotherapy in participants with advanced or metastatic Biliary tract cancer.
Studientyp
Einschreibung (Geschätzt)
Phase
- Phase 2
Kontakte und Standorte
Studienkontakt
- Name: AstraZeneca Clinical Study Information Center
- Telefonnummer: 1-877-240-9479
- E-Mail: information.center@astrazeneca.com
Studienorte
-
-
-
Melbourne, Australien, 3000
- Rekrutierung
- Research Site
-
Murdoch, Australien, WA6150
- Rekrutierung
- Research Site
-
Randwick, Australien, 2031
- Rekrutierung
- Research Site
-
-
-
-
-
Changsha, China, 410013
- Noch keine Rekrutierung
- Research Site
-
Chengdu, China, 610041
- Noch keine Rekrutierung
- Research Site
-
-
-
-
-
Tbilisi, Georgia, 0112
- Rekrutierung
- Research Site
-
-
-
-
-
Chūōku, Japan, 104-0045
- Rekrutierung
- Research Site
-
Kashiwa, Japan, 227-8577
- Rekrutierung
- Research Site
-
Kitaadachi-gun, Japan, 362-0806
- Rekrutierung
- Research Site
-
Kōtoku, Japan, 135-8550
- Rekrutierung
- Research Site
-
Nagoya, Japan, 464-8681
- Rekrutierung
- Research Site
-
Osakasayama-shi, Japan, 589-8511
- Rekrutierung
- Research Site
-
-
-
-
Ontario
-
Kingston, Ontario, Kanada, K7L 2V7
- Zurückgezogen
- Research Site
-
Toronto, Ontario, Kanada, M5G 2M9
- Rekrutierung
- Research Site
-
-
Quebec
-
Montreal, Quebec, Kanada, H3G 1A4
- Rekrutierung
- Research Site
-
Sherbrooke, Quebec, Kanada, J1G 2E8
- Rekrutierung
- Research Site
-
-
-
-
-
George Town, Malaysia, 10450
- Rekrutierung
- Research Site
-
Johor Bahru, Malaysia, 81100
- Abgeschlossen
- Research Site
-
Kuala Lumpur, Malaysia, 59100
- Rekrutierung
- Research Site
-
Kuala Selangor, Malaysia, 62250
- Rekrutierung
- Research Site
-
Kuching, Malaysia, 93586
- Rekrutierung
- Research Site
-
-
-
-
-
Chisinau, Moldawien, MD-2025
- Rekrutierung
- Research Site
-
-
-
-
-
Krakow, Polen, 31-501
- Rekrutierung
- Research Site
-
Warsaw, Polen, 02-034
- Rekrutierung
- Research Site
-
-
-
-
-
Bukit Merah, Singapur, 169610
- Rekrutierung
- Research Site
-
Singapore, Singapur, 308433
- Rekrutierung
- Research Site
-
Singapore, Singapur, 119074
- Rekrutierung
- Research Site
-
Singapore, Singapur, 329563
- Rekrutierung
- Research Site
-
-
-
-
-
Barcelona, Spanien, 08035
- Rekrutierung
- Research Site
-
Madrid, Spanien, 28007
- Rekrutierung
- Research Site
-
Madrid, Spanien, 28040
- Rekrutierung
- Research Site
-
-
-
-
-
Gyeonggi-do, Südkorea, 13620
- Rekrutierung
- Research Site
-
Seoul, Südkorea, 03080
- Rekrutierung
- Research Site
-
Seoul, Südkorea, 06351
- Rekrutierung
- Research Site
-
Seoul, Südkorea, 05505
- Rekrutierung
- Research Site
-
Seoul, Südkorea, 03722
- Rekrutierung
- Research Site
-
-
-
-
-
Kaohsiung City, Taiwan, 80756
- Rekrutierung
- Research Site
-
Taichung, Taiwan, 404
- Rekrutierung
- Research Site
-
Tainan, Taiwan, 70403
- Rekrutierung
- Research Site
-
Taipei, Taiwan, 11217
- Rekrutierung
- Research Site
-
Taoyuan, Taiwan, 00333
- Rekrutierung
- Research Site
-
-
-
-
California
-
Orange, California, Vereinigte Staaten, 92868
- Rekrutierung
- Research Site
-
Palo Alto, California, Vereinigte Staaten, 94304
- Rekrutierung
- Research Site
-
Santa Rosa, California, Vereinigte Staaten, 95403
- Rekrutierung
- Research Site
-
-
Kentucky
-
Louisville, Kentucky, Vereinigte Staaten, 40202
- Rekrutierung
- Research Site
-
-
New York
-
Commack, New York, Vereinigte Staaten, 11725
- Rekrutierung
- Research Site
-
-
Rhode Island
-
Providence, Rhode Island, Vereinigte Staaten, 02903
- Rekrutierung
- Research Site
-
-
Texas
-
Houston, Texas, Vereinigte Staaten, 77030
- Rekrutierung
- Research Site
-
-
-
-
-
Glasgow, Vereinigtes Königreich, G12 0YN
- Zurückgezogen
- Research Site
-
Leeds, Vereinigtes Königreich, LS9 7TF
- Zurückgezogen
- Research Site
-
London, Vereinigtes Königreich, NW3 2QG
- Zurückgezogen
- Research Site
-
Oxford, Vereinigtes Königreich, OX3 7LE
- Zurückgezogen
- Research Site
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
The list below is a summarised eligibility criteria for the study - refer to the study protocol for full criteria.
Master Inclusion Criteria applicable to all sub studies:
- Participant must be ≥ 18 years or the legal age of consent at the time of signing the ICF.
- Participants who are CLDN18.2 positive.
- Must have at least one measurable lesion according to RECIST v1.1.
- ECOG performance status of 0 to 1 with no deterioration over the previous 2 weeks prior first day of dosing.
- Predicted life expectancy of ≥ 12 weeks.
- Adequate organ and bone marrow function as defined by protocol.
- Body weight > 35 kg.
- Participants are willing to comply with contraception requirements.
Sub study 1 Specific Inclusion criteria:
- Histologically confirmed adenocarcinoma of the stomach or gastroesophageal junction.
- Advanced or metastatic GC/GEJC.
- Maximum 2 prior lines of systemic treatment for unresectable or metastatic disease.
Sub study 2 Specific Inclusion criteria:
- Participants diagnosed with histologically confirmed metastatic or advanced PDAC.
- Availability of an archival sample or a fresh tumour biopsy taken at screening.
- No prior treatments for unresectable or metastatic disease. Prior neoadjuvant/adjuvant chemotherapy is permitted as long as participants progressed ≥ 6 months (183 days) from the last dose.
Sub study 3 Specific Inclusion criteria
- Histologically confirmed, unresectable advanced, or metastatic adenocarcinoma of biliary tract, including cholangiocarcinoma (intrahepatic or extrahepatic) and gallbladder carcinoma (NOTE: Ampullary cancers are not eligible).
- Documented radiographic or clinical disease progression on or after at least one prior regimen and maximum 2 prior lines of systemic treatment for unresectable or metastatic disease.
Master Exclusion Criteria applicable to all sub studies:
- Unstable or active peptic ulcer disease or digestive tract bleeding including but not limited to clinically significant bleeding in the setting of prior CLDN18.2 directed therapy.
- Participants with clinically significant ascites that require drainage.
- A history of drug-induced non-infectious ILD/pneumonitis.
- Central nervous system metastases or CNS pathology.
- Peripheral neuropathy, sensory, or motor ≥ Grade 2 at screening.
- History of another primary malignancy.
- Prior exposure to any MMAE-based ADC.
- Prior exposure to any CLDN18.2 targeted agents except anti-CLDN18.2 monoclonal antibody.
Sub study 1 Specific Exclusion criteria:
- Participants with HER2-positive (3+ by IHC, or 2+ by IHC, and positive by ISH) or indeterminate GC/GEJC unless they have failed/not tolerated/or are not eligible for standard anti-HER2 therapy, where available.
- Any factors that increase the risk of QTc prolongation or risk of arrhythmic events.
- The use of concomitant medications known to prolong the QT/QTc interval.
Sub study 2 Specific Exclusion criteria:
- Known DPD enzyme deficiency based on local testing where testing is SoC.
- Use of strong inhibitor or inducer of UGT1A1.
- Use of strong inhibitors or inducers of CYP3A4.
- Known homozygous for the UGT1A1*28 allele based on local testing where testing is SoC.
Sub study 3 Specific Exclusion criteria
• Clinically significant biliary obstruction that has not resolved before enrollment.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Sub Study 1 - AZD0901 MONOTHERAPY
Sub Study 1 will investigate AZD0901 monotherapy in order to evaluate the safety, tolerability, and efficacy of AZD0901. |
Antibody-drug conjugate/Biologic
Andere Namen:
|
|
Experimental: Sub Study 2 - AZD0901 IN COMBINATION WITH ANTI-CANCER AGENTS IN PANCREATIC DUCTAL ADENOCARCINOMA
Substudy 2 will investigate the safety and efficacy of AZD0901 as first line systemic treatment used in combination with different chemotherapy agents |
Antibody-drug conjugate/Biologic
Andere Namen:
Chemotherapy agents
Andere Namen:
Chemotherapy agents
Andere Namen:
Chemotherapy agents
Andere Namen:
Chemotherapy agents
Andere Namen:
Chemotherapy agents
Andere Namen:
Chemotherapy agents
Andere Namen:
|
|
Experimental: Sub Study 3: AZD0901 MONOTHERAPY IN BILIARY TRACT CANCER
Substudy 3 Further evaluate the preliminary anti-tumour activity of AZD0901 monotherapy by assessment of DRR. |
Antibody-drug conjugate/Biologic
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Incidence of adverse events (AEs), serious AEs (SAEs). Changes from baseline in clinical laboratory parameters, vital signs, ECGs and physical examination. Rate of AEs leading to discontinuation of AZD0901, Occurrence of DLTs.
Zeitfenster: 30 days post treatment completion. AE Follow Up for 90 days post AZD0901 discontinuation.
|
To investigate the safety and tolerability, of AZD0901 monotherapy or in combination with anti-cancer agents in particpants with advanced or metastatic solid tumours expressing CLDN18.2. |
30 days post treatment completion. AE Follow Up for 90 days post AZD0901 discontinuation.
|
|
Objective Response Rate (ORR).
Zeitfenster: From date of first dose of AZD0901 up until progression, or the last evaluable assessment in the absence of progression (approximately 2 years).
|
Proportion of participants with a confirmed Complete Response (CR) or Partial Response (PR) as determined by the Investigator at local site as per RECIST v1.1. |
From date of first dose of AZD0901 up until progression, or the last evaluable assessment in the absence of progression (approximately 2 years).
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Overall Survival (OS)
Zeitfenster: From date of first dose/randomisation until the date of death due to any cause (approximately 2 years).
|
The analysis will include all dosed/randomised participants as assigned/randomised. All deaths will be included, regardless of whether the participant withdraws from therapy or receives another anticancer therapy. |
From date of first dose/randomisation until the date of death due to any cause (approximately 2 years).
|
|
Progression Free Survival (PFS)
Zeitfenster: From date of first dose/randomisation until disease progression or death in the absence of progression (approximately 2 years).
|
Progression-free survival is defined as the time date of randomisation or enrollment until progression per RECIST v1.1 as assessed by the Investigator at local site, or death due to any cause, regardless of whether the participant withdraws from randomized therapy, receives another anti-cancer therapy or clinically progresses prior to RECIST v1.1 progression. |
From date of first dose/randomisation until disease progression or death in the absence of progression (approximately 2 years).
|
|
Duration of Response (DoR)
Zeitfenster: From the date of first documented confirmed response until date of documented progression (approximately 2 years).
|
The time from the date of first documented confirmed response until date of first documented progression per RECIST v1.1 or death due to any cause. |
From the date of first documented confirmed response until date of documented progression (approximately 2 years).
|
|
Disease control rate (DCR)
Zeitfenster: Up to 11 weeks post date of first dose/randomisation
|
The percentage of participants who have a confirmed CR or PR or who have SD per RECIST v1.1 as assessed by the Investigator at local site and derived from the raw tumour data up to 11 weeks after date of first dose/randomisation. |
Up to 11 weeks post date of first dose/randomisation
|
|
Percentage change in tumor size
Zeitfenster: From start through to study completion.
|
The best percentage change from baseline in tumor size is the largest decrease (or smallest increase) from baseline for a participant, using RECIST v1.1 assessments. |
From start through to study completion.
|
|
Serum concentration of AZD0901 (total ADC), total antibody (conjugated and unconjugated) and total unconjugated MMAE
Zeitfenster: From date of first dose of AZD0901 up until 90 days post AZD0901 discontinuation.
|
To characterise the PK of AZD0901 monotherapy or in combination with anti cancer agents in participants with advanced or metastatic solid tumours expressing CLDN18.2. |
From date of first dose of AZD0901 up until 90 days post AZD0901 discontinuation.
|
|
Serum PK parameters of AZD0901, total antibody (conjugated and unconjugated) and MMAE including but not limited to AUC, Cmax, tmax, clearance and half-life, as data allow.
Zeitfenster: From date of first dose of AZD0901 up until 90 days post AZD0901 discontinuation.
|
To characterise the PK of AZD0901 monotherapy or in combination with anti cancer agents in participants with advanced or metastatic solid tumours expressing CLDN18.2. |
From date of first dose of AZD0901 up until 90 days post AZD0901 discontinuation.
|
|
Clinical activity by baseline and/or on-treatment tissue-based biomarkers including, but not limited to, gene expression, mutation profiles, DNA damage, protein expression, immune response and/or mechanisms of resistance.
Zeitfenster: From date of first dose of AZD0901 up to 7 weeks.
|
To investigate baseline and/or on-treatment tissue-based RNA, DNA, and/or proteins, and association with clinical activity of AZD0901 (substudy 1). |
From date of first dose of AZD0901 up to 7 weeks.
|
|
ADA status will be determined along with prevalence and incidence of anti-drug antibodies to AZD0901, and titer established.
Zeitfenster: From date of first dose of AZD0901 up until 90 days post AZD0901 discontinuation.
|
To determine the immunogenicity of AZD0901 monotherapy or in combination with anti-cancer agents in participants with advanced or metastatic solid tumours expressing CLDN18.2. |
From date of first dose of AZD0901 up until 90 days post AZD0901 discontinuation.
|
Mitarbeiter und Ermittler
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Neubildungen nach Standort
- Neubildungen
- Gastrointestinale Neubildungen
- Neoplasmen des Verdauungssystems
- Erkrankungen des Verdauungssystems
- Magen-Darm-Erkrankungen
- Magenerkrankungen
- Erkrankungen der Gallenwege
- Magenneoplasmen
- Neoplasien der Gallenwege
- Heterocyclische Verbindungen, 1-Ring
- Heterocyclische Verbindungen
- Heterocyclische Verbindungen, 2-Ring
- Heterocyclische Verbindungen, Fusionsring
- Camptothecin
- Alkaloide
- Enzyme und Coenzyme
- Desoxycytidin
- Cytidin
- Pyrimidin -Nucleoside
- Pyrimidine
- Formyltetrahydrofolate
- Tetrahydrofolate
- Folsäure
- Pterins
- Pteridine
- Uracil
- Pyrimidinone
- Coenzyme
- Irinotecan
- Gemcitabin
- Fluoruracil
- Leucovorin
- Irinotecan -Sucrosofat
Andere Studien-ID-Nummern
- D9800C00001
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
"Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.
IPD-Sharing-Zeitrahmen
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
IPD-Sharing-Zugriffskriterien
When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Art der unterstützenden IPD-Freigabeinformationen
- STUDIENPROTOKOLL
- SAFT
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .